Kindt M V, Heikkila R E
Life Sci. 1986 Apr 21;38(16):1459-62. doi: 10.1016/0024-3205(86)90558-8.
Pretreatment of mice with the potent and selective monoamine oxidase B (MAO-B) inhibitor MDL 72145 ((E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine) protected against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Mice treated with MDL 72145 prior to MPTP did not exhibit the decrement in the neostriatal content of dopamine and its metabolites normally seen after MPTP administration. This observation adds further support to the concept that the oxidation of MPTP by MAO-B to its corresponding pyridinium analog, 1-methyl-4-phenylpyridinium (MPP+), is an important feature of the neurotoxic process.
用强效选择性单胺氧化酶B（MAO-B）抑制剂MDL 72145（（E）-2-（3'，4'-二甲氧基苯基）-3-氟烯丙胺）对小鼠进行预处理，可预防1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）的多巴胺能神经毒性。在给予MPTP之前用MDL 72145处理的小鼠，其新纹状体中多巴胺及其代谢产物的含量并未出现MPTP给药后通常所见的减少。这一观察结果进一步支持了以下概念，即MAO-B将MPTP氧化为其相应的吡啶鎓类似物1-甲基-4-苯基吡啶鎓（MPP +）是神经毒性过程的一个重要特征。
